Brad Bundy develops cell‑free transcription–translation platforms for protein and virus‑like particle production. He integrates noncanonical amino acids and site‑specific immobilization to enhance stability and function, enabling on‑demand biomanufacturing, biosensing, and therapeutic prototyping.